Apnimed
  • About
    • Apnimed Team
    • Board of Directors
    • Scientific Advisory Board
    • Careers
  • Obstructive Sleep Apnea
  • Our Science
    • Publications
  • Clinical Research
    • Expanded Access Policy
  • Pipeline
  • News
    • Events
    • Insights
  • Contact Us
Select Page

Apnimed Announces Dosing of First Patient in Phase 2 MARIPOSA Confirmatory Trial of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea (OSA)

Dec 16, 2021

– Study to Inform Phase 3 Program Design of AD109 and Advance Program for AD504 – Topline Results Expected Mid-2022  CAMBRIDGE, Mass. December 16, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address...

Apnimed Achieves Meaningful Results in Proof-of-Concept Crossover Study with Oral Therapeutic Candidates AD504 and AD182 for the Treatment of Obstructive Sleep Apnea

Nov 16, 2021

– Primary and secondary endpoints showed promising results for the treatment of OSA as compared to placebo – Both candidates demonstrated a favorable safety profile    CAMBRIDGE, Mass. November 16, 2021 – Apnimed, a clinical-stage pharmaceutical company focused...

Apnimed Announces Positive Phase 2 Data (Study APC-004) Demonstrating Improvement in Measures of Obstructive Sleep Apnea and a Dose-Response with AD109, an Oral Pharmacologic Treatment for the Disease

Oct 13, 2021

– Primary and key secondary endpoints showed statistically significant and clinically meaningful benefit in patients with mild to moderate OSA – AD109 was safe and well-tolerated at both doses studied – Data from a second Phase 2 study (APC-003) in patients with more...

Apnimed Announces Positive Phase 2 (Study APC-003) Data Demonstrating Durability-of-Effect and Improved Quality-of-Life in Patients with Obstructive Sleep Apnea After Investigational AD109 Treatment

Oct 13, 2021

– Primary and key secondary endpoints showed statistically significant and clinically meaningful benefit in patients with mild to severe OSA – Data showed evidence of durability-of-effect and improved quality-of-life and quality-of-sleep in open-label study extension...

Apnimed Expands Executive Leadership Team Appointing Rob Rode Chief Commercial Officer

Sep 27, 2021

CAMBRIDGE, Mass. September 27, 2021 – Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for obstructive sleep apnea and related disorders, today announced that Rob Rode has joined the company as Chief Commercial Officer. Mr. Rode has more...

Apnimed to Present at the Canaccord Genuity 41st Annual Growth Conference

Aug 5, 2021

CAMBRIDGE, Mass. August 6, 2021 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that the Company’s management team will participate in the Canaccord...
« Older Entries

News

  • 2020
  • 2021
  • 2022
  • 2023
  • Events
  • Insights
  • Past Events
  • About
  • Obstructive Sleep Apnea
  • Our Science
  • Clinical Research
  • Pipeline
  • News
  • Careers
  • Contact Us
  • Twitter

Privacy Policy | Terms and Conditions

©2023 Apnimed. All rights reserved. Apnimed is a Cambridge, MA-based clinical-stage company dedicated to the discovery of novel therapies for sleep apnea and related disorders. The characterization of the discovery and development efforts on this website, as well as the expectations associated with them, are reflective of the current state of development and may change as the Company progresses.